🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Recruitingn/aAges 12 Years - 89 YearsAllCastle Biosciences Incorporated
NCT07645820 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Participants may be eligible if they: * Are 12 to 89 years old. * Have been diagnosed with atopic dermatitis (eczema). * Have had at least one atopic dermatitis flare within the past 2 months. * Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits. * If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study. Exclusion Criteria: Participants may not be eligible if they: * Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements. * Do not have suitable skin areas for study measurements. * Have another skin condition that may affect study assessments. * Are pregnant.
💊

What it tests

  • Nevisense electrical impedance spectroscopy
📍

Where

13 sites
U.S. Dermatology Partners
Phoenix, United States
James Y. Wang MD, Inc
Los Angeles, United States
U.S. Dermatology Partners Rockville
Rockville, United States
Derm Research Institute, PLC
Caledonia, United States
U.S. Dermatology Partners Lee's Summit
Lee's Summit, United States
Advanced Dermatology and Cosmetic Surgery - Henderson
Henderson, United States
Las Vegas Dermatology
Las Vegas, United States
StracSkin, PLLC
Portsmouth, United States

…and 5 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy